medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2022, Number 3

<< Back Next >>

Alerg Asma Inmunol Pediatr 2022; 31 (3)

Experience with the use of dupilumab in patients with eosinophilic asthma

Cerda-Reyes S, Castillón-Benavides NK, Campos-Gutiérrez RI, Maldonado-Hernández JG, Cuevas MHA

Language: Spanish
References: 23
Page: 84-89
PDF size: 165.50 Kb.


ABSTRACT

Introduction: eosinophilic asthma is the most common phenotype of severe asthma. Dupilumab was approved for use in Mexico in 2017 as an adjunctive treatment for severe uncontrolled asthma with T2 and/or eosinophilic phenotype in patients 12 years of age. Objective: to evaluate the response to Dupilumab in Mexican patients with severe eosinophilic asthma. Material and methods: observational study in Mexican patients, in whom the response to dupilumab was evaluated after 12 months of treatment. Results: after 12 months of treatment with dupilumab, a reduction in exacerbations, improvement in the ACT questionnaires, reduction in the need for rescue bronchodilators and in the dose of maintenance controllers was documented; improvement in FEV1. Conclusion: dupilumab is an effective medication in the management of patients with severe uncontrolled asthma with T2 and/or eosinophilic phenotype, with no adverse effects to date.


REFERENCES

  1. Castro M, Corren J, Pavord ID et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 378 (26): 2486-2496.

  2. Opina MT, Moore WC. Phenotype-driven therapeutics in severe asthma. Curr Allergy Asthma Rep. 2017; 17 (2): 10.

  3. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017; 377 (10): 965-976.

  4. Rathinam KK, Abraham JJ, Vijayakumar TM. Dupilumab in the treatment of moderate to severe asthma: an evidence-based review. Curr Ther Res Clin Exp. 2019; 91: 45-51.

  5. Katial RK, Bensch GW, Busse WW et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract. 2017; 5 (2S): S1-S14.

  6. Narendra D, Blixt J, Hanania NA. Immunological biomarkers in severe asthma. Semin Immunol. 2019; 46 :101332.

  7. Jones TL, Neville DM, Chauhan AJ. Diagnosis and treatment of severe asthma: a phenotype-based approach. Clin Med (Lond). 2018; 18 (Suppl 2): s36-s40.

  8. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020; 50 (1): 5-14.

  9. Worm M, Simpson EL, Thaci D et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020; 156 (2): 131-143.

  10. Wollenberg A, Beck LA, Blauvelt A et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020; 182 (5): 1120-1135.

  11. Simpson EL, Paller AS, Siegfried EC et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020; 156 (1): 44-56.

  12. Xiong XF, Zhu M, Wu HX, Fan LL, Cheng DY. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019; 20 (1): 108.

  13. Brooks GD. Updated evaluation of dupilumab in the treatment of asthma: patient selection and reported outcomes. Ther Clin Risk Manag. 2020; 16: 181-187.

  14. Rabe KF, Nair P, Brusselle G et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; 378 (26): 2475-2485.

  15. Deeks ED. Dupilumab: a review in moderate to severe asthma. Drugs. 2019; 79 (17): 1885-1895.

  16. Mavissakalian M, Brady S. The current state of biologic therapies for treatment of refractory asthma. Clin Rev Allergy Immunol. 2020; 59 (2): 195-207.

  17. Corren J, Castro M, Chanez P et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019; 122 (1): 41-49.e2.

  18. Agache I, Akdis CA, Akdis M et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021; 76 (1): 14-44.

  19. Lo R, McGhee S. Is dupilumab effective in treating uncontrolled moderate-to-severe asthma? J Allergy Clin Immunol Pract. 2019; 7 (5): 1705-1706.

  20. Wechsler ME, et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J All Clin Immunol Pract. 2022;10:2695-709

  21. Barry K, Gorelik D. Dupilumab (dupixent) for asthma. Am Fam Physician. 2020; 101 (4): 244-245.

  22. Akenroye A, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022; 150(5): 1097–1105.

  23. Hanania NA et al. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023 (130) : 206−214




2020     |     www.medigraphic.com